Cronos Group Inc. (NASDAQ:CRON) Receives $2.30 Average PT from Analysts

Shares of Cronos Group Inc. (NASDAQ:CRON) have been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $2.30.

Several equities analysts have issued reports on the company. Canaccord Genuity Group initiated coverage on Cronos Group in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cronos Group in a report on Monday, December 29th. Zacks Research downgraded Cronos Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $2.30 price target on shares of Cronos Group in a research note on Wednesday, January 14th. Finally, Wall Street Zen downgraded shares of Cronos Group from a “hold” rating to a “sell” rating in a report on Saturday.

Institutional Investors Weigh In On Cronos Group

Institutional investors and hedge funds have recently modified their holdings of the company. Jones Financial Companies Lllp boosted its position in Cronos Group by 291.6% during the first quarter. Jones Financial Companies Lllp now owns 65,099 shares of the company’s stock worth $118,000 after purchasing an additional 48,476 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Cronos Group by 84.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,076,405 shares of the company’s stock worth $1,948,000 after buying an additional 493,161 shares during the last quarter. Envestnet Asset Management Inc. purchased a new stake in shares of Cronos Group in the 2nd quarter worth about $36,000. Bastion Asset Management Inc. purchased a new position in Cronos Group during the 2nd quarter valued at about $619,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Cronos Group by 161.5% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,000 shares of the company’s stock valued at $240,000 after acquiring an additional 77,200 shares in the last quarter. Institutional investors and hedge funds own 8.71% of the company’s stock.

Cronos Group Stock Performance

Shares of Cronos Group stock opened at $2.67 on Tuesday. Cronos Group has a one year low of $1.60 and a one year high of $3.43. The company has a market cap of $1.02 billion, a P/E ratio of -266.73 and a beta of 0.80. The firm has a fifty day moving average of $2.65 and a two-hundred day moving average of $2.60.

Cronos Group (NASDAQ:CRON) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. The business had revenue of $58.39 million for the quarter, compared to analyst estimates of $38.51 million. Cronos Group had a negative net margin of 6.44% and a negative return on equity of 1.26%. As a group, equities analysts predict that Cronos Group will post -0.03 earnings per share for the current year.

Key Stories Impacting Cronos Group

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q4 revenue and EPS beat — Net revenue rose materially and results topped Street expectations: Q4 net revenue rose ~47% year-over-year to roughly $44.5M, and the company reported $0.02 EPS versus consensus ~$0.01, beating estimates. This topline and EPS surprise is the primary driver behind supportive price action. MarketBeat Earnings
• Positive Sentiment: Record revenue streak and brand strength — Cronos reported record Q4 and FY 2025 net revenue (eight consecutive quarters of record revenue in Israel) and noted PEACE NATURALS® leadership in that market, supporting top-line durability. GlobeNewswire Release
• Positive Sentiment: Strong balance sheet — Management highlighted an industry-leading cash and short-term investments position (~$832M), which reduces near-term financing risk and supports strategic optionality (M&A, Europe expansion, product investment). Yahoo Finance Release
• Neutral Sentiment: Strategic moves in Europe amid regulatory headwinds — Management discussed expansion/strategic initiatives in Europe, but flagged regulatory challenges that could slow commercialization; this is a potential growth driver but carries execution and regulatory risk. Yahoo Earnings Highlights
• Neutral Sentiment: Short-interest reporting ambiguous — Recent short-interest data in one feed showed no meaningful, actionable change (reporting anomalies); not a clear immediate catalyst. Monitor updated short-interest releases for clarity. Short Interest Note
• Negative Sentiment: Forex drove a Q4 GAAP loss — Currency translation/FX transactions swung the company to a Q4 loss (small per-share loss) and contributed to a FY net loss (~$9.4M), which investors may penalize as recurring FX volatility or accounting charges. Seeking Alpha FX Loss Story
• Negative Sentiment: Margins and profitability metrics mixed — While net margin on reported period activity looked strong, the company still posted a negative return on equity and a small full-year loss, keeping profitability questions on the table for some investors. MarketWatch Coverage

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.